Some doctors recommend its supplementation to treat cancer, as it increases the effectiveness of chemotherapy drugs and reduces their toxicity
Enjoy fruits like papaya, orange, and lemon as breakfast items or healthy snack options
Stamm 16 , Karen Sims 17 , Michele Anderson 16 , Gaston Picchio 17 , Grace Wang 16 , Rozalina Balabanska 18 , Radoslava Tsrancheva 19 and Jacob George 20 , (1)Department of Hepatology and Liver Transplant Unit, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia, (2)Toronto Liver Center, Toronto, Ontario, Canada, (3)University Multiprofile Hospital for Active Treatment St Ivan Rilski, Sofia, Bulgaria, (4)Footscray Hospital, Footscray, Victoria, Australia, (5)Liverpool Hospital, Liverpool, New South Wales, Australia, (6)Toronto General Hospital, Toronto, Ontario, Canada, (7)Centre Hospitalier De lUniversit De Montral, (8)Bailey Health Center, Edmonton, AB, Canada, (9)Saint George Hospital, Kogarah, New South Wales, Australia, (10)Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, (11)The Alfred, Melbourne, Victoria, Australia, (12)Centre Hospitalier Universitaire De Qubec Universit Laval, Qubec, Qubec, Canada, (13)Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, (14)St Vincents Hospital Sydney, Darlinghurst, New South Wales, Australia, (15)Nov Rehabilitatsionen Tsentar Eood, Stara, Bulgaria, (16)Assembly Biosciences, Inc., South San Francisco, CA, (17)Arbutus Biopharma, Warminster, PA, (18)Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria, (19)Diagnostic Consultative Center Aleksandrovska, Sofia, Bulgaria, (20)Storr Liver Centre, Westmead Hospital, Westmead Millennium Institute for Medical Research and University of Sydney, Westmead, New South Wales, Australia Background: This open-label study assessed the safety and efficacy of vebicorvir (VBR)+AB-729+nucleos(t)ide reverse transcriptase inhibitor (NrtI) in virologically suppressed (VS) patients (pts) with hepatitis B e antigen (eAg) negative chronic hepatitis B infection (NCT04820686)
Conclusion: Certain combinations of common genetic variants in cholestasis-associated genes show an association with cholestatic enzyme profiles and may be causally involved in the development of previously unexplained cholestatic liver injury
